This program is intended for healthcare professionals outside the United States only.
Primary Sclerosing Cholangitis (PSC)
Login
Register
This program is intended for healthcare professionals outside the United States only.
Popular searches
Popular searches

AASLD 2025 Reflections: Key takeaways in primary sclerosing cholangitis

  • PSC, Video
Leave your feedback

Dr Marlyn Mayo and Dr Andreas Kremer provide a concise expert overview of the key highlights from AASLD The Liver Meeting 2025, with a focus on hepatology advances in primary sclerosing cholangitis (PSC). In this video they discuss new signals of progress in PSC from promising PPAR agonist and IBAT inhibition data to a growing focus on fatigue, anxiety, and quality-of-life outcomes.

This video offers subtitles in English, French, Portuguese, and Spanish, which can be enabled using the subtitle icon  in the video player.

Enjoyed this? You might like:

  • Video
  • AASLD 2025

AASLD 2025 Reflections: Key takeaways in late-onset genetic cholestasis

Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.
Watch now
  • Video
  • AASLD 2025

AASLD 2025 Reflections: Key takeaways in primary biliary cholangitis

Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.
Watch now
  • Video
  • AASLD 2025

Seladelpar improves wellbeing and lowers itch impact

Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.
Watch now
  • Video
  • AASLD 2025

Survey reveals limitations to pruritus assessment in PSC

Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.
Watch now
  • News article
  • AASLD 2025

Ongoing seladelpar treatment continues to benefit PBC patients

Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.
Find out more
  • News article
  • AASLD 2025

Maralixibat offers clinically meaningful pruritus reductions in PSC

A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.
Find out more
  • News article
  • AASLD 2025

Genetic etiology may explain majority of adult-onset cholestatic disorders

Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.
Find out more
  • News article
  • AASLD 2025

Next generation sequencing may offer diagnoses in adult unexplained cholestasis

Adults living with unexplained cholestasis could receive a diagnosis with next generation sequencing, suggests US study.
Find out more
  • Video
  • AASLD 2025

Gut microbiome may influence PSC development

Marios Nikolaidis shares findings on the gut microbiome in PSC management.
Watch now
  • News article
  • AASLD 2025

Digital mind–body intervention helps symptom management in liver disease

A mind–body intervention accessed online may help patients with liver disease better manage their symptoms.
Find out more
Primary Sclerosing Cholangitis (PSC)